Autonomix Medical Secures Two EuroPCR 2026 Abstracts on Pancreatic Cancer Pain Data
Autonomix Medical had two abstracts accepted for presentation at EuroPCR 2026, highlighting its transvascular RF ablation platform’s role in pancreatic cancer pain mitigation and precision-guided nerve imaging. The presentations underscore growing clinical interest in the company’s catheter-based microchip sensing technology and could advance its platform toward broader indications and trials.
1. Abstract Acceptances at EuroPCR 2026
Autonomix Medical will present two posters at EuroPCR 2026 in Paris (May 19–22). The first abstract, “Pain mitigation in pancreatic cancer: An analysis of denervation via transvascular RF ablation,” details long-term pain reduction data, while the second, “Illuminating the nervous system with transvascular precision-guided technology,” showcases imaging capabilities of its platform.
2. Innovative Transvascular Platform Technology
The company’s catheter-based microchip sensing array is designed to detect and differentiate neural signals with high sensitivity. Its transvascular RF ablation approach targets peripheral nerves through blood vessels, enabling minimally invasive diagnosis and modulation of nerve pathways implicated in pain and other disease states.
3. Clinical and Strategic Implications
Acceptance at a leading cardiovascular intervention meeting bolsters clinical validation and raises visibility among key opinion leaders. Engagement with the interventional community could drive collaborations, support future trials across cardiology and chronic pain indications, and accelerate development milestones.